1. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Issue 10 (October 2021) Authors: Cudkowicz, Merit; Genge, Angela; Maragakis, Nicholas; Petri, Susanne; van den Berg, Leonard; Aho, Valtteri V; Sarapohja, Toni; Kuoppamäki, Mikko; Garratt, Chris; Al-Chalabi, Ammar; Kiernan, Matthew; Mathers, Susan; Henderson, Robert; Needham, Merrilee; Schultz, David; Löscher, Wolfgang; Mitrovic,... Journal: Lancet neurology Issue: Volume 20:Issue 10(2021) Page Start: 821 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The NEALS primary lateral sclerosis registry. (2nd November 2020) Authors: Paganoni, Sabrina; De Marchi, Fabiola; Chan, James; Thrower, Sara K.; Staff, Nathan P.; Datta, Neil; Kisanuki, Yaz Y.; Drory, Vivian; Fournier, Christina; Pioro, Erik P.; Goutman, Stephen A.; Atassi, Nazem; Jeon, Maryangel; Caldwell, Sarah; Mcdonough, Timothy; Gentile, Caroline; Liu, Jianing; Tur... Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 21(2020)Supplement 1 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗